{
  "id": "602343051cb411341a00008d",
  "type": "factoid",
  "question": "What is the target of Volanesorsen?",
  "ideal_answer": "Volanesorsen is a second-generation antisense oligonucleotide inhibiting apoC-III (apolipoprotein C-III) transcription/translation that has been recently approved in Europe for Familial Chylomicronemia Syndrome (FCS) treatment.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31390883",
    "http://www.ncbi.nlm.nih.gov/pubmed/29889589",
    "http://www.ncbi.nlm.nih.gov/pubmed/32753844",
    "http://www.ncbi.nlm.nih.gov/pubmed/27271183",
    "http://www.ncbi.nlm.nih.gov/pubmed/32589506",
    "http://www.ncbi.nlm.nih.gov/pubmed/28595549",
    "http://www.ncbi.nlm.nih.gov/pubmed/29096837",
    "http://www.ncbi.nlm.nih.gov/pubmed/31390500",
    "http://www.ncbi.nlm.nih.gov/pubmed/32646313",
    "http://www.ncbi.nlm.nih.gov/pubmed/30403015",
    "http://www.ncbi.nlm.nih.gov/pubmed/32511037",
    "http://www.ncbi.nlm.nih.gov/pubmed/28300080",
    "http://www.ncbi.nlm.nih.gov/pubmed/32494907",
    "http://www.ncbi.nlm.nih.gov/pubmed/31301033",
    "http://www.ncbi.nlm.nih.gov/pubmed/29124482",
    "http://www.ncbi.nlm.nih.gov/pubmed/31032598",
    "http://www.ncbi.nlm.nih.gov/pubmed/30596391"
  ],
  "snippets": [
    {
      "text": "Treatment with Volanesorsen, a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32589506",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32646313",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Volanesorsen is a second-generation antisense oligonucleotide inhibiting apoC-III transcription/translation that has been recently approved in Europe for Familial Chylomicronemia Syndrome (FCS) treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32646313",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Volanesorsen is an antisense oligonucleotide (ASO) inhibitor of apoC3, which reduces TG levels by 70-80% which has been shown also to reduce rates of pancreatitis and improve well-being in FCS and reduce TGs and improve insulin resistance in FPLD. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753844",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Volanesorsen targeting apoC-III has shown reductions in plasma TG levels up to 90%. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32511037",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CENT FINDINGS: Evidence is now emerging that volanesorsen, a second-generation antisense oligonucleotide drug targeting ApoCIII messenger RNA resulting in decreases in TG in patients with familial chylomicronemia syndrome, severe hypertriglyceridemia, and metabolic dyslipidemia with type 2 diabetes giving support to the hypothesis that ApoCIII is a powerful inhibitor of LPL, and when reduced, endogenous clearance of TRLs can result in substantial reductions in TG levels. D",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29124482",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To determine the effects of volanesorsen (ISIS 304801), a second-generation 2'-O-methoxyethyl chimeric antisense inhibitor of apolipoprotein (apo)C-III, on triglyceride (TG) levels and insulin resistance in patients with type 2 diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27271183",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ariants. As such, apoC-III has been recognised as a potential therapeutic target for patients with severe hypertriglyceridaemia with one of the most promising apoC-III-targeting drugs, volanesorsen, having recently progressed through Phase III ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32494907",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Volanesorsen, is an antisense oligonucleotid that inhibits the production of the Apo C-III which is crucial in regulating TGs metabolism because it inhibits lipoprotein lipase (LPL) and hepatic lipase activity but also hepatic uptake of TGs-rich particles.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30403015",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Some new drugs are on the horizon, such as volanesorsen (which targets apolipoprotein C-III), pemafibrate, and others.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28300080",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Volanesorsen is an experimental antisense oligonucleotide that inhibits translation of Apo-CIII mRNA, thereby substantially lowering plasma levels of Apo-CIII and triglycerides.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30596391",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Volanesorsen, an investigational inhibitor of apoC-III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by marked chylomicronemia leading to a spectrum of symptoms, including recurrent abdominal pain and episodes of potentially fatal acute pancreatitis (AP).OBJECTIVE: To determine the effect of volanesorsen on burden of disease on patients with FCS Methods: ReFOCUS was a retrospective global web-based survey open to patients with FCS who received volanesorsen for \u22653\u00a0months in an open",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29889589",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In an open-label study of three patients with this syndrome, antisense-mediated inhibition of hepatic APOC3 mRNA with volanesorsen led to decreased plasma apolipoprotein C-III and triglyceride levels.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31390500",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Volanesorsen (Waylivra\u00ae), an antisense oligonucleotide inhibitor of apolipoprotein CIII (apoCIII) mRNA, is being developed by Ionis Pharmaceuticals through its subsidiary company, Akcea Therapeutics, to treat familial chylomicronemia syndrome (FCS), hypertriglyceridemia and familial partial lipodystrophy (FPL). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31301033",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Recently, volanesorsen as a promising ApoIII inhibitor was shown to improve the lipid profile in patients with diabetic dyslipidemia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31032598",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "he antisense oligonucleotide (ASO) against APOC3 mRNA volanesorsen (previously called ISIS 304801, ISIS-ApoCIIIRx and IONIS-ApoCIIIRx) robustly decreases both, apoC-III production and triglyceride concentrations and is being currently evaluated in phase 3 trials. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28595549",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The antisense oligonucleotide (ASO) against APOC3 mRNA volanesorsen (previously called ISIS 304801, ISIS-ApoCIIIRx and IONIS-ApoCIIIRx) robustly decreases both, apo-CIII production and triglyceride concentrations and is being currently evaluated in phase 3 trials. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29096837",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "et, it remains unclear whether apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance and whether apoC-III antisense therapy (volanesorsen) affects distribution of apoC-III glycoforms. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31390883",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "apoC-III"
}